Infigratinib is an orally administered ATP competitive, selective tyrosine kinase inhibitor that inhibits FGFR. It is being investigated for the treatment of FGFR-driven conditions, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (urinary tract and bladder cancer), and other FGFR-driven cancer(s).

Infigratinib is an investigational therapy and its safety and efficacy have not been established.

There is no guarantee that infigratinib will receive health authority approval or become commercially available in any country for the uses being investigated.

Infigratinib is co-developed globally by AMPL Healthcare S.A. and QED Therapeutics, Inc. in all fields of use except for skeletal dysplasias and except in the following territories: China, Hong Kong and Macau.